Percutaneous photoacoustic debulking of infra-inguinal atherosclerotic disease- early European experience with a novel, solid-state, pulsed -wave, ultraviolet 355 nm laser

医学 经皮 揭穿 动脉切除术 血运重建 外科 外围设备 严重肢体缺血 放射科 再狭窄 支架 内科学 血管疾病 动脉疾病 心肌梗塞 卵巢癌 癌症
作者
Waclaw B. Kuczmik,Grzegorz Oszkinis,Łukasz Kruszyna,Michał-Goran Stanišić,Wojciech Żelawski,Jacek Kostecki,David Planer,Luis R. León,Yossi Muncher,Oshrat Cohen,On Topaz
出处
期刊:Lasers in Medical Science [Springer Science+Business Media]
卷期号:40 (1): 4-4 被引量:6
标识
DOI:10.1007/s10103-024-04216-7
摘要

The broad spectrum of clinical manifestations caused by peripheral arterial disease [PAD] and the morphologic heterogeneity of associated atherosclerotic lesions present a considerable management challenge. Endovascular interventions are recognized an effective treatment for PAD. Within this revascularization strategy the role of atherectomy debulking modalities continue to evolve. Accordingly, the study herein assessed the efficacy and safety of a novel, solid state, Nd: YAG pulsed-wave [355 nm wavelength] laser atherectomy in the treatment of symptomatic infra-inguinal PAD. The EX-PAD-01 study, a prospective, single-arm, open label trial enrolled 50 patients (38 males, 12 females; mean age 64 years] with symptomatic peripheral arterial disease, who underwent percutaneous revascularization with a novel, solid state, pulsed-wave [355 nm wavelength] laser atherectomy followed with adjunct treatment. The Ankle-brachial index [ABI], Rutherford classification for chronic limb ischemia and the walking impairment questionnaire [WIQ] were used for assessment of the index clinical condition of the enrolled patients, for post procedure evaluation and during follow-up. Accordingly, the patients were followed for 12-months with repeated direct physician contact visits. Fifty-three atherosclerotic stenoses (51 femoropopliteal, 2 tibial) with a mean length of 7.4 cm. (ranged 1cm to 25cm) were treated. There were 79% occlusions, and 61% containing moderate-to-severe calcifications. The pre-procedure stenosis was 95.3 ± 10.3%, the Rutherford classification for chronic limb ischemia [CLI] was 2.90 ± 0.54 ranging between 2-4 and the WIQ 34.6 ± 8.62. Technical success was achieved in 52 of the 53 (98%) target lesions. Following laser debulking the baseline stenosis was reduced from 95.3 ± 10.3% to 61.3 ± 25.5% [ [p < 0.0001] and with adjunct balloon/stenting to final of 14.0 ± 14.0% [p < 0.0001]. Embolic protection devices were utilized in 6 [12%] patients. At 30-day post procedure evaluation the ABI increased from baseline of 0.57 ± 0.14 to 0.94 ± 0.14 [p < 0.0001] and no major adverse effects or device adverse effects were detected. At 6 months follow -up the ABI was 0.84 ± 0.20% (p < 0.0001 vs. initial) and at 1 year follow-up 0.79 ± 0.16 (P = 0.0001 vs. initial) without major adverse events. Out of 46 [92%] patients who reached the 12 months follow-up mark, 2 [4.3%] experienced clinically driven target lesion revascularization. Sustained clinical benefit for up to 12 months post procedure was demonstrated through documentation of statistically significant decrease of Rutherford CLI class as well as concomitant improvement in WIQ score and an increase of ABI value. The primary patency rate, as defined by peak systolic velocity ratio (PSVR) of < 2.5m/second was 95.7% (22 of 23) and 81.8% (18 of 22) at 6 months and 12 months, respectively. In an early European clinical experience with a series of 50 patients with symptomatic peripheral arterial disease, the novel Nd: YAG solid state, pulsed- wave 355nm cardiovascular laser atherectomy device provided effective and safe revascularization treatment. Follow-up at 6 and 12 months, respectively, substantiate the efficacy, safety profile and clinical merits of this novel laser. Thus, this device is useful in the management of select patients with symptomatic infra-inguinal atherosclerotic lesions.Clinical Trial Registration: Clinical trials.gov number: NTC02556255.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chen发布了新的文献求助10
刚刚
哈哈w发布了新的文献求助10
刚刚
称心的谷菱完成签到 ,获得积分10
1秒前
zhiruiwang完成签到,获得积分10
1秒前
针真滴完成签到 ,获得积分10
1秒前
斯文败类的应助被细腻驳采纳,获得10
1秒前
sunshine完成签到,获得积分10
1秒前
苹果听枫完成签到,获得积分10
1秒前
2秒前
黎谱完成签到,获得积分10
2秒前
Liu完成签到,获得积分10
3秒前
3秒前
satellite完成签到,获得积分10
3秒前
十一完成签到 ,获得积分10
3秒前
Ujana完成签到,获得积分10
3秒前
一叶知秋完成签到,获得积分10
4秒前
star完成签到 ,获得积分10
4秒前
神勇初瑶完成签到,获得积分10
4秒前
seedcode完成签到,获得积分10
4秒前
4秒前
李爱国的应助被呋喃采纳,获得10
4秒前
结果诠释过往完成签到 ,获得积分10
5秒前
Maestro_S的应助被黄家宝采纳,获得10
6秒前
冷酷以山完成签到,获得积分10
6秒前
gxiaxia完成签到,获得积分10
7秒前
Owen的应助被心殇采纳,获得30
7秒前
无知完成签到,获得积分10
7秒前
Xc完成签到,获得积分10
7秒前
7秒前
h11的应助被yy采纳,获得10
8秒前
8秒前
111完成签到,获得积分10
8秒前
章海鹏完成签到 ,获得积分10
8秒前
erhya完成签到,获得积分10
8秒前
顾矜的应助被王kk采纳,获得10
8秒前
华仔的应助被Rony采纳,获得10
8秒前
9秒前
hustzwqq完成签到,获得积分10
9秒前
典雅的雪晴完成签到,获得积分10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464